QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
NASDAQ:BIIB

Biogen - BIIB Stock Forecast, Price & News

$288.28
+4.65 (+1.64%)
(As of 02/6/2023 12:00 AM ET)
Add
Compare
Today's Range
$285.08
▼
$292.26
50-Day Range
$270.81
▼
$305.17
52-Week Range
$187.16
▼
$311.88
Volume
782,649 shs
Average Volume
1.14 million shs
Market Capitalization
$41.51 billion
P/E Ratio
14.68
Dividend Yield
N/A
Price Target
$312.56

Biogen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
8.4% Upside
$312.56 Price Target
Short Interest
Healthy
1.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.85
Upright™ Environmental Score
News Sentiment
0.16mentions of Biogen in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$1.68 M Sold Last Quarter
Proj. Earnings Growth
-7.78%
From $17.10 to $15.77 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

362nd out of 1,027 stocks

Biological Products, Except Diagnostic Industry

57th out of 169 stocks

See Top Rated MarketRank™ Stocks Here
BIIB stock logo

About Biogen (NASDAQ:BIIB) Stock

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

BIIB Stock News Headlines

January 30, 2023 | marketbeat.com
Cassava Sciences Stock Undervalued with Its $124 Price Target? (BIIB)
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a
February 6, 2023 | finance.yahoo.com
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
February 6, 2023 | Wall Street Watch Dogs (Ad)
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
February 6, 2023 | finance.yahoo.com
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
February 6, 2023 | seekingalpha.com
Biogen: What To Do Ahead Of Q4 2022 Financial Report
February 1, 2023 | stocknews.com
3 Biotech Stocks to Get in on Before It’s Too Late
February 1, 2023 | americanbankingnews.com
Biogen Inc. (NASDAQ:BIIB) Receives $309.14 Average Target Price from Analysts
January 31, 2023 | americanbankingnews.com
Biogen Inc. (NASDAQ:BIIB) Short Interest Up 10.5% in January
February 6, 2023 | Investing Trends (Ad)
Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
January 30, 2023 | finance.yahoo.com
UPDATE 1-Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen
January 29, 2023 | finance.yahoo.com
LECANEMAB RECEIVES PRIORITY REVIEW STATUS IN JAPAN
January 28, 2023 | americanbankingnews.com
Analysts Offer Predictions for Biogen Inc.'s FY2027 Earnings (NASDAQ:BIIB)
January 27, 2023 | americanbankingnews.com
Needham & Company LLC Comments on Biogen Inc.'s FY2022 Earnings (NASDAQ:BIIB)
January 27, 2023 | americanbankingnews.com
Biogen Inc. (NASDAQ:BIIB) Forecasted to Earn Q4 2022 Earnings of $3.56 Per Share
January 26, 2023 | finance.yahoo.com
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
January 26, 2023 | finance.yahoo.com
UPDATE 1-EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen
January 26, 2023 | markets.businessinsider.com
Where Biogen Stands With Analysts
January 26, 2023 | marketwatch.com
Biogen Inc. stock outperforms market despite losses on the day
January 26, 2023 | marketwatch.com
Biogen Inc. stock outperforms market on strong trading day
January 26, 2023 | finance.yahoo.com
The Petri Dish: Morphic, J&J part ways; FDA committee to review another Biogen drug
January 24, 2023 | finance.yahoo.com
Biogen Inc. (BIIB) Stock Moves -0.02%: What You Should Know
January 24, 2023 | finance.yahoo.com
Why Biogen Inc. (BIIB) Could Beat Earnings Estimates Again
January 24, 2023 | stocknews.com
1 High-Yield Dividend Stock You Can Count on in 2023
January 20, 2023 | finance.yahoo.com
Why the FDA didn’t grant an approval to Lilly’s Alzheimer’s drug
January 20, 2023 | finance.yahoo.com
The FDA Rejected Lilly’s Alzheimer’s Drug. Why It’s Only a Setback,
January 20, 2023 | finance.yahoo.com
In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug
January 20, 2023 | finance.yahoo.com
Eli Lilly Stock Slips Lower As FDA Rejects Fast Track Approval For Alzheimer's Drug
See More Headlines
Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

BIIB Company Calendar

Last Earnings
10/19/2021
Today
2/06/2023
Next Earnings (Confirmed)
2/15/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BIIB
CUSIP
09062X10
CIK
875045
Web
www.biogen.com
Phone
(617) 679-2000
Fax
617-679-2617
Employees
9,610
Year Founded
1978

Price Target and Rating

Average Stock Price Forecast
$312.56
High Stock Price Forecast
$370.00
Low Stock Price Forecast
$225.00
Forecasted Upside/Downside
+8.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
26 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$19.64
Trailing P/E Ratio
14.68
Forward P/E Ratio
16.86
P/E Growth
1.8
Net Income
$1.56 billion
Net Margins
27.64%
Pretax Margin
32.74%
Return on Equity
21.31%
Return on Assets
10.24%

Debt

Debt-to-Equity Ratio
0.49
Current Ratio
2.49
Quick Ratio
2.14

Sales & Book Value

Annual Sales
$10.98 billion
Price / Sales
3.78
Cash Flow
$27.61 per share
Price / Cash Flow
10.44
Book Value
$74.61 per share
Price / Book
3.86

Miscellaneous

Outstanding Shares
144,000,000
Free Float
143,065,000
Market Cap
$41.51 billion
Optionable
Optionable
Beta
0.22

Social Links


Key Executives

  • Christopher A. Viehbacher
    President, Chief Executive Officer & Director
  • Alphonse Galdes
    EVP-Pharmaceutical Operations & Technology
  • Michael R. McDonnell
    Chief Financial Officer & Executive Vice President
  • Mahalakshmi Radhakrishnan
    Chief Medical Officer & Group Senior VP
  • Priya Singhal
    Executive VP, Head-Research & Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BIIB Stock - Frequently Asked Questions

Should I buy or sell Biogen stock right now?

26 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 7 hold ratings and 19 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIIB shares.
View BIIB analyst ratings or view top-rated stocks.

What is Biogen's stock price forecast for 2023?

26 brokers have issued twelve-month price objectives for Biogen's stock. Their BIIB share price forecasts range from $225.00 to $370.00. On average, they anticipate the company's share price to reach $312.56 in the next twelve months. This suggests a possible upside of 8.4% from the stock's current price.
View analysts price targets for BIIB or view top-rated stocks among Wall Street analysts.

How have BIIB shares performed in 2023?

Biogen's stock was trading at $276.92 at the beginning of 2023. Since then, BIIB shares have increased by 4.1% and is now trading at $288.28.
View the best growth stocks for 2023 here.

Are investors shorting Biogen?

Biogen saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 1,890,000 shares, an increase of 10.5% from the December 31st total of 1,710,000 shares. Based on an average daily trading volume, of 1,300,000 shares, the days-to-cover ratio is presently 1.5 days. Approximately 1.3% of the shares of the company are short sold.
View Biogen's Short Interest.

When is Biogen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 15th 2023.
View our BIIB earnings forecast.

How can I listen to Biogen's earnings call?

Biogen will be holding an earnings conference call on Wednesday, February 15th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) released its quarterly earnings data on Tuesday, October, 19th. The biotechnology company reported $4.77 earnings per share for the quarter, beating analysts' consensus estimates of $4.09 by $0.68. The biotechnology company had revenue of $2.78 billion for the quarter, compared to the consensus estimate of $2.67 billion. Biogen had a net margin of 27.64% and a trailing twelve-month return on equity of 21.31%. Biogen's quarterly revenue was down 17.7% on a year-over-year basis. During the same period in the prior year, the company earned $8.84 earnings per share.
Read the conference call transcript.

What is Michel Vounatsos' approval rating as Biogen's CEO?

394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Who are Biogen's major shareholders?

Biogen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.37%), Sumitomo Mitsui Trust Holdings Inc. (0.36%), Parnassus Investments LLC (0.21%), Los Angeles Capital Management LLC (0.14%), New York State Common Retirement Fund (0.11%) and New York State Teachers Retirement System (0.11%). Insiders that own company stock include Alfred Sandrock, Brian S Posner, Ginger Gregory, Michel Vounatsos, Stephen A Sherwin and Susan H Alexander.
View institutional ownership trends.

How do I buy shares of Biogen?

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $288.28.

How much money does Biogen make?

Biogen (NASDAQ:BIIB) has a market capitalization of $41.51 billion and generates $10.98 billion in revenue each year. The biotechnology company earns $1.56 billion in net income (profit) each year or $19.64 on an earnings per share basis.

How many employees does Biogen have?

The company employs 9,610 workers across the globe.

Does Biogen have any subsidiaries?
The following companies are subsidiares of Biogen: BIIB Colombia S.A.S., Biogen (Argentina) SRL, Biogen (Bermuda) Technologies Ltd., Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (RTP) Realty LLC, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd, Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Digital Health Inc., Biogen Estonia OU, Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hong Kong Limited, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Limited, Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia S.R.L., Biogen Japan Ltd., Biogen Korea LLC, Biogen Latvia SIA, Biogen Lithuania UAB, Biogen Luxembourg Holding S.a.r.l., Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma d.o.o., Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o., Biogen Poland Sp. z.o.o., Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen Turkey Ilac Ticaret Limited Sirketi, Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Limited, Eidetica Biopharma GmbH, Fumapharm, IDEC Pharmaceuticals Corporation, NightstaRx Limited, Nightstar Europa Limited, Nightstar Inc., Nightstar Therapeutics Limited, Nightstar Therapeutics plc, Old Convergence Pharmaceuticals Limited, Panima Pharmaceuticals AG, Silver Acquisition Co. Ltd., Stromedix Inc., Stromedix Inc., Syntonix Pharmaceuticals Inc., TYSABRI, and Tungsten Bidco Limited.
Read More
How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.biogen.com. The biotechnology company can be reached via phone at (617) 679-2000, via email at ir@biogen.com, or via fax at 617-679-2617.

This page (NASDAQ:BIIB) was last updated on 2/6/2023 by MarketBeat.com Staff